Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H.

Breast. 2011 Oct;20 Suppl 3:S1-11. doi: 10.1016/S0960-9776(11)70287-9.

2.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
3.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Goel S, Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Review.

PMID:
19821328
4.
5.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
6.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
7.

LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

Sharma R, Hamilton A, Beith J.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. doi: 10.1002/14651858.CD004562.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.

PMID:
18843661
8.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

10.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Lancet. 2004 Sep 4-10;364(9437):858-68.

PMID:
15351193
11.

Changing role of the oestrogen receptor in the life and death of breast cancer cells.

Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H.

Breast. 2003 Dec;12(6):432-41. Review.

PMID:
14659118
12.
13.

Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?

Bhattacharya P, Abderrahman B, Jordan VC.

Expert Rev Anticancer Ther. 2017 Apr;17(4):297-310. doi: 10.1080/14737140.2017.1297233. Epub 2017 Mar 10.

PMID:
28281842
14.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.

Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.

15.

Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.

McDaniel RE, Maximov PY, Jordan VC.

Vitam Horm. 2013;93:1-49. doi: 10.1016/B978-0-12-416673-8.00007-1. Review.

PMID:
23810002
16.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
17.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
18.
19.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

20.

Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.

Goldhirsch A.

Breast. 2013 Aug;22 Suppl 2:S3-7. doi: 10.1016/j.breast.2013.07.001. Review.

PMID:
24074788

Supplemental Content

Support Center